Fight Bladder Cancer supports evidence-based medicine for all those affected by bladder cancer
A clinical trial is something that can be offered at any part in the bladder cancer journey, from initial suspected diagnosis, through investigations and different treatment, and in later follow up, or at end of life.
There are a number of clinical trials in bladder cancer. These usually compare a new treatment which has the potential of working better or with less side effects, with what is used as the “gold-standard”.
Different trials are available in different hospitals. This is because of either the complexity of the trial or because of the type of treatment or test involved. For example, studies of surgery or radiotherapy may only be open at the particular hospital or cancer centres where the operation or the radiotherapy takes place. All studies have particular tick boxes to confirm whether this study is the correct one for you and your cancer. It may be that you and your type of bladder cancer do not match what we call the eligibility criteria (or check list) for the study.
You should ask your doctor if you are suitable for a clinical trial, and it is always helpful to take information with you for any trials that your doctor may not be familiar with. If the study is open elsewhere in the UK and it looks as though you may be eligible for this (and are prepared to travel), you could ask your doctor to refer you.
Current Open Bladder Cancer Trials
Suspected bladder cancer
This trial will need a urine sample from participants who are under investigation for possible bladder cancer and are due to undergo a standard of care investigative cystoscopy and biopsy. This study is testing to see whether the UroX biomarker can be detected in urine samples and therefore be a way of diagnosing patients. Both healthy and bladder cancer participants are needed.
ClinicalTrials.gov ID: NCT03973307
Newly detected or recurrent bladder cancer
After being diagnosed with bladder cancer, patients will be asked to provide a urine sample. The urine samples will be used to develop better ways of diagnosing bladder cancer in the future.
ClinicalTrials.gov ID: NCT03664258
Non-invasive bladder cancer
This study is for people with non-muscle invasive bladder cancer. Patients will receive nivolumab treatment, with the possible addition of BCG, BMS-986205, or BMS-986205 + BCG. This is a study looking at how well these treatments work in people with non-muscle invasive bladder cancer.
ClinicalTrials.gov ID: NCT03519256
This project will develop and evaluate a patient-reported symptom index to assess the impact of treatment for non-muscle invasive bladder cancer on patient burden, toxicity, symptoms and side-effects. The symptom index will provide a method for assessing treatments from the patients' perspective; help healthcare professionals make better informed treatment decisions, and provide a method to be able to effectively evaluate treatments for non-muscle invasive bladder cancer.
ClinicalTrials.gov ID: NCT03091764
This study is for people who have high-risk non-muscle invasive bladder cancer that is persistent or recurrent following BCG induction. Patients will receive a drug called pembrolizumab along with BCG, or BCG without pembrolizumab. This is a study looking at how well pembrolizumab works together with BCG in people with bladder cancer.
ClinicalTrials.gov ID: NCT03711032
Advanced or metastatic bladder cancer
This study is for people with Muscle-Invasive Bladder Cancer. This study is looking at whether a type of immunotherapy drug called durvalumab can be safely administered after initial treatment received by a patient. This study is to determine whether durvalumab given after standard trimodality therapy (maximal transurethral resection of the bladder tumor (TURBT) followed by concurrent chemotherapy and radiation) improves disease-free-survival when compare to surveillance alone.
ClinicalTrials.gov ID: NCT03768570
This study is to redesign the management pathway for patients with muscle-invasive bladder cancer by using an MRI scan rather than doing a transurethral resection of a bladder tumour (TURBT), to diagnose and more accurately and rapidly stage their cancer.
International Trial Number: ISRCTN35296862
This study is for people who have locally advanced or metastatic bladder cancer. Patients will receive a drug called atezolizumab in combination with a new drug called cabozantinib. This is a very early study looking at the safety and ideal dose of cabozantinib.
ClinicalTrials.gov ID: NCT03170960
This study is for people who have locally advanced or metastatic bladder cancer. Patients will receive a personalised cancer vaccine called RO7198457, with the possible addition of a drug called atezolizumab. This is an early study looking at the safety and ideal doses of the drugs.
ClinicalTrials.gov ID: NCT03289962
This study is for people who have muscle-invasive bladder cancer, and who are not eligible for cisplatin-based chemotherapy. Patients will receive either surgery alone, pembrolizumab plus surgery, or enfortumab vedotin plus pembrolizumab plus surgery. This is a study looking at how well pembrolizumab and enfortumab vedotin work together with surgery in people with bladder cancer.
ClinicalTrials.gov ID: NCT03924895
This study is for people who have muscle-invasive bladder cancer. Patients will receive a drug called pembrolizumab along with chemotherapy and bladder removal, or chemotherapy and bladder removal without pembrolizumab. This is a study looking at how well pembrolizumab works together with chemotherapy and surgery in people with bladder cancer.
ClinicalTrials.gov ID: NCT03924856
This is a study for people with metastatic or inoperable bladder cancer who test positive for the FGFR (Fibroblast Growth Factor Receptor) alteration biomarker. This study will be used to test the ideal dose of two drugs called erdafitinib and cetrelimab, as well as to test their safety and how well they work.
ClinicalTrials.gov ID: NCT03473743
This is a study for people with advanced bladder cancer who test positive for the FGFR biomarker. Patients will receive either chemotherapy, a drug called erdafitinib, or a drug called pembrolizumab. This study will test how well these drugs work in people with bladder cancer.
ClinicalTrials.gov ID: NCT03390504
This is a study for people with advanced bladder cancer who test positive for the FGFR biomarker. Patients will receive either a drug called derazantinib, or both derazantinib and another drug called atezolizumab. This is a very early study looking at the safety and ideal dose of derazantinib.
ClinicalTrials.gov ID: NCT04045613
This study is for people who have advanced or metastatic bladder cancer, and who either test positive for the PD-L1 biomarker or who are not eligible for chemotherapy. Patients will receive a drug called pembrolizumab, and perhaps another drug called lenvatinib. This is a study looking at how well these drugs work together in people with bladder cancer.
ClinicalTrials.gov ID: NCT03898180
This study is for people who have advanced or metastatic bladder cancer, who have been previously treated with chemotherapy. Patients will receive a drug called atezolizumab. This is a study looking at how well this drug works in people with bladder cancer.
ClinicalTrials.gov ID: NCT03782207
For people who have advanced or metastatic bladder cancer, who have progressed during or following chemotherapy. Patients will receive a drug called atezolizumab, and perhaps one of the following drugs: enfortumab vedotin, niraparib, Hu5F9-G4, tiragolumab, sacituzumab govitecan, tocilizumab, RO7122290 or RO7121661.
ClinicalTrials.gov ID: NCT03869190
For people who have advanced or metastatic bladder cancer. Patients will receive a drug called LY3143921. This is an early study looking at the safety and ideal doses of the drug.
ClinicalTrials.gov ID: NCT03096054
This study is looking at the drug RP1 alone and then RP1 in combination with nivolumab. This trial needs participants with advanced and/or refractory solid tumours. The is a phase 1 and phase 2 trial and is being done to determine the maximum tolerated dose and recommended phase 2 dose of the drug. It is for a range of cancers but includes bladder cancer.
ClinicalTrials.gov ID: NCT03767348
This study is for people with muscle invasive bladder cancer. Its aim is to determine the efficiency and safety of the immunotherapy drug durvalumab in combination with the chemotherapy drugs gemcitabine and cisplatin. It is a phase 3 clinical trial and will use the drugs durvalumab, cisplatin and gemcitabine. Patients must be planning to undergo a radical cystectomy to be eligible.
ClinicalTrials.gov ID: NCT03732677
This is for people with muscle invasive bladder cancer. This study is looking at the use of the drug nivolumab with chemotherapy or nivolumab and BMS-986205 (another drug) with chemotherapy followed by continued immune-oncology therapy and comparing it to just chemotherapy. It will look at the success of the addition of the drugs.
ClinicalTrials.gov ID: NCT03661320
This study will look at the safety and tolerability of the drug S-588210 in people with unresectable recurrent and/or metastatic solid tumours. This trial is for multiple different cancers, but includes bladder cancer. Participants will receive injections once a week for four weeks and then biweekly for 8 weeks of the new drug.
ClinicalTrials.gov ID: NCT04316689
This study is looking at the safety and tolerability of the drug MRx0518 in people with solid tumours at 30 days post-surgery. It is a phase 1 clinical trial and the trial will look at the drugs' anti-cancer and immune system modulating properties. Patients will need to be amenable to surgical resection.
ClinicalTrials.gov ID: NCT03934827
Our research team
The Fight Bladder Cancer Research Division is currently working to progress the Fight Bladder Cancer Exemplar Study, develop further patient experience surveys and support Fight Bladder Cancer's involvement in ongoing clinical trials.
We campaign for a number of areas of research that are essential and long overdue, to give patients better survival and quality of life.
Find out more about how we can support trials & research.
Please contact us direct for any further information requirements on 01844 351621 or use the contact form below or email us direct at firstname.lastname@example.org
Fight Bladder Cancer has not conducted or funded research involving animals, does not currently conduct or fund research involving animals, and has no plans to do so in the future.
Fight Bladder Cancer supports research that will lead to better survival and quality of life for bladder cancer patients, with a focus on projects that have a direct impact on patient care.
Research & Fight Bladder Cancer
Get in touch
We’ve done everything we can to make all the information on this site as accurate as possible. Whilst we have had support from a small team of medical professionals advisors to review the general medical content of this site, please remember, that only YOUR medical team can give YOU specific advice about YOUR symptoms or illness. We encourage you to discuss any potential options with them.